Timeline (parent company Amazentis) is a Lausanne-based consumer health biotech focused on Mitopure®, a proprietary ingredient designed to improve mitochondrial function and support healthy aging. Mitopure® is backed by over 15 years of research, multiple clinical studies and more than 50 patents and is clinically proven to target a cellular longevity pathway. Timeline incorporates Mitopure® into next-generation nutritional supplements and topical skin health products. The company plans to expand its science, product categories, and markets across food, beauty, and health sectors and to build the brand in consumer longevity. Nestlé Health Science has been an investor since 2019. Timeline recently completed a significant financing to support these growth plans. Based in Lausanne, Switzerland, Amazentis develops products targeting mitochondrial health for advanced nutrition and pharmaceutical applications. Its proprietary lead product candidate, AMAZ-02, is an oral formulation of urolithin A that stimulates mitophagy to improve mitochondrial function in muscle. The company has reported preclinical results in Nature Medicine and presented Phase 1 clinical safety and translational data. Amazentis has established an extensive intellectual property portfolio and proprietary know‑how around urolithin A. With the recently completed Series C financing, the company plans to advance two pivotal Phase 2 trials (ENERGIZE and ATLAS) and to prepare for future commercial activities. The clinical program is focused on validating AMAZ-02 as a solution to support healthy aging and improve muscle function.

Total raised

$74M

Funding rounds

2

Latest round

Series D

Latest activity

Jan 2024